Gene therapy in pancreatic cancer

doi:10.3748/wjg.v20.i37.13343

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 37

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (15949)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-7) series.

Item

Count

PDF

790

WORD

351

HTML

9515

Figures (1-3)

361

Tables (1-7)

285

Sum=11302

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

568

Download

790

Sum=1358

Publishing Process of This Article

Item

Count

Browse

1677

Download

1612

Sum=3289

Oct 7, 2014 (publication date) through Feb 14, 2025

Times Cited of This Article

Times Cited (40)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Oct 7, 2014; 20(37): 13343-13368
Published online Oct 7, 2014. doi: 10.3748/wjg.v20.i37.13343

Table 4 Antigenic sources used in pancreatic cancer vaccine trials

Peptide or protein vaccines	Mutant K-ras peptide
	WT1 peptide
	CAP1-6D
	G17DT
	HLA-A*0201 restricted VEGF receptor-1 and -2 peptides
	HLA-A24 restricted survivin-2B80-88 peptide (AYACNTSTL)
	Autologous heat shock protein HSPPC-96
	TELOVAC
Whole cell vaccines or dendritic cell vaccines	α-Gal transferase transfected allogeneic tumor cells (including Algenpantucel-L)
	GVAX
	MUC-1 pulsed autologous dendritic cells
Viral or bacterial vaccines	PANVAC-VF-MUC-1, CEA, and TRICOM transfected virus
	Mesothelin (CRS-207) transfected live-attenuated Listeria
DNA vaccines	VXMO1

VXMO1: VEGF receptor-2 DNA vaccine; GVAX: GM-CSF transfected allogeneic tumor cells; TELOVAC: Telomerase peptide GV1001; CAP1-6D: CEA peptide; WT1: Wilms tumor 1; G17DT: Gastrin peptide.

Citation: Liu SX, Xia ZS, Zhong YQ. Gene therapy in pancreatic cancer. World J Gastroenterol 2014; 20(37): 13343-13368
URL: https://www.wjgnet.com/1007-9327/full/v20/i37/13343.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i37.13343